Up 12.5%!!! During his first term, Trump emphasize

Up 12.5%!!! During his first term, Trump emphasized deregulation and aimed to streamline the drug approval process through initiatives like the Right to Try Act (which expanded access to experimental drugs) and Fast Track initiatives for certain therapies. He also appointed FDA commissioners like Scott Gottlieb, who, although focused on public health, pushed for more efficient approval processes while still maintaining safety standards. This could be seen as positive for biotech companies, as it might lead to faster approvals for new drugs and treatments.

Having said that. I'm bullish on a buyout more than ever now because of this.